BRPI1011015B8 - método para sintetizar pirfenidona - Google Patents

método para sintetizar pirfenidona

Info

Publication number
BRPI1011015B8
BRPI1011015B8 BRPI1011015A BRPI1011015A BRPI1011015B8 BR PI1011015 B8 BRPI1011015 B8 BR PI1011015B8 BR PI1011015 A BRPI1011015 A BR PI1011015A BR PI1011015 A BRPI1011015 A BR PI1011015A BR PI1011015 B8 BRPI1011015 B8 BR PI1011015B8
Authority
BR
Brazil
Prior art keywords
pirfenidone
disclosed
synthesizing
butanol
ethyl acetate
Prior art date
Application number
BRPI1011015A
Other languages
English (en)
Inventor
Cyr Mike
Radhakrishnan Ramachandran
Marie-Francoise Brigitte Boutet Sabine
Original Assignee
Intermune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43298478&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI1011015(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Intermune Inc filed Critical Intermune Inc
Publication of BRPI1011015A2 publication Critical patent/BRPI1011015A2/pt
Publication of BRPI1011015B1 publication Critical patent/BRPI1011015B1/pt
Publication of BRPI1011015B8 publication Critical patent/BRPI1011015B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C07D213/643—2-Phenoxypyridines; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/34—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom
    • A01N43/40—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Agronomy & Crop Science (AREA)
  • Pest Control & Pesticides (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Plant Pathology (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

método aperfeiçoado para sintetizar pirfenidona. um processo para sintetizar pirfenidona de bromobenzeno tendo menos de cerca de 0,15% em peso de dibromobenzo é divulgado. também são divulgados processo para sintetizar pirfenidona sem usar acetado de etila ou n-butanol e pirfenidona tendo níveis controlados de acetado de etila, n-butanol, di (5-metil-2-piridinona)benzenos e outras impurezas tendo tempos de retenção especificados. também são divulgadas formas de dosagem formuladas incluindo a pirfenidona divulgada.
BRPI1011015A 2009-06-03 2010-06-02 método para sintetizar pirfenidona BRPI1011015B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18358809P 2009-06-03 2009-06-03
US61/183,588 2009-06-03
PCT/US2010/037090 WO2010141600A2 (en) 2009-06-03 2010-06-02 Improved method for synthesizing pirfenidone

Publications (3)

Publication Number Publication Date
BRPI1011015A2 BRPI1011015A2 (pt) 2018-02-14
BRPI1011015B1 BRPI1011015B1 (pt) 2020-11-10
BRPI1011015B8 true BRPI1011015B8 (pt) 2021-05-25

Family

ID=43298478

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1011015A BRPI1011015B8 (pt) 2009-06-03 2010-06-02 método para sintetizar pirfenidona

Country Status (35)

Country Link
US (6) US20110003863A1 (pt)
EP (1) EP2440543B1 (pt)
JP (2) JP5848244B2 (pt)
KR (1) KR101734858B1 (pt)
CN (1) CN102482255A (pt)
AP (1) AP3630A (pt)
AR (1) AR076974A1 (pt)
AU (1) AU2010256693B2 (pt)
BR (1) BRPI1011015B8 (pt)
CA (1) CA2764043C (pt)
CL (1) CL2011003069A1 (pt)
DK (1) DK2440543T3 (pt)
EA (1) EA021826B1 (pt)
ES (1) ES2538103T3 (pt)
GE (1) GEP20156223B (pt)
HN (1) HN2011003187A (pt)
HR (1) HRP20150696T1 (pt)
HU (1) HUE026014T2 (pt)
IL (1) IL216565A (pt)
MA (1) MA33489B1 (pt)
MX (1) MX2011012654A (pt)
MY (1) MY162443A (pt)
NI (1) NI201100211A (pt)
NZ (1) NZ596872A (pt)
PE (1) PE20120398A1 (pt)
PL (1) PL2440543T3 (pt)
PT (1) PT2440543E (pt)
RS (1) RS54031B1 (pt)
SG (1) SG176648A1 (pt)
SI (1) SI2440543T1 (pt)
TN (1) TN2011000615A1 (pt)
TW (1) TWI434833B (pt)
UA (1) UA106759C2 (pt)
WO (1) WO2010141600A2 (pt)
ZA (1) ZA201108794B (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2010012848A (es) 2008-06-03 2011-03-01 Intermune Inc Compuestos y metodos para tratar trastornos inflamatorios y fibroticos.
DK2670242T3 (da) 2011-01-31 2022-05-02 Avalyn Pharma Inc Aerosolpirfenidon- og pyridonanalogforbindelser og anvendelser deraf
US10105356B2 (en) 2011-01-31 2018-10-23 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
CA2936330C (en) 2014-01-10 2023-01-03 Genoa Pharmaceuticals Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
CN106459042B (zh) 2014-04-02 2019-06-28 英特穆恩公司 抗纤维化吡啶酮类
BR112017002980A2 (pt) * 2014-08-15 2017-12-12 Pixarbio Corp composição para inibir a inflamação em um indivíduo com um dano na coluna vertebral, método para tratar inflamação em um indivíduo tendo um dano na coluna vertebral e kit para produzir a composição
WO2016122420A1 (en) 2015-01-26 2016-08-04 Ulkar Kimya Sanayii Ve Ticaret A. S. An improved method for the synthesis and purification of pirfenidone
ITUB20154832A1 (it) * 2015-10-29 2017-04-29 Procos Spa Processo per la sintesi di pirfenidone
CN105315198A (zh) * 2015-11-02 2016-02-10 重庆康乐制药有限公司 一种吡非尼酮的晶型及其制备方法
CN105330598B (zh) * 2015-12-02 2017-11-14 新发药业有限公司 一种吡非尼酮的制备方法
WO2017122139A1 (en) * 2016-01-14 2017-07-20 Laurus Labs Limited An improved process for the preparation of pirfenidone
US11066368B2 (en) 2016-01-14 2021-07-20 Laurus Labs Limited Process for the preparation and particle size reduction of pirfenidone
WO2017130166A1 (en) * 2016-01-31 2017-08-03 Granules India Limited An improved process for the preparation of highly pure anti-fibrotic drug
CA2937365C (en) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
IT201600071672A1 (it) * 2016-07-08 2018-01-08 Dipharma Francis Srl Metodo per sintetizzare un farmaco immunosoppressore
IT201600108927A1 (it) * 2016-10-27 2018-04-27 Dipharma Francis Srl Metodo per sintetizzare un farmaco antifibrotico
US20180009753A1 (en) * 2016-07-08 2018-01-11 Dipharma Francis S.R.L. Method for preparing an antifibrotic agent
WO2018083709A1 (en) * 2016-11-07 2018-05-11 Msn Laboratories Private Limited, R&D Center Improved process for the preparation of pure 5-methyl-1-phenyl-2-1 (h)-pyridone
WO2018178996A1 (en) * 2017-03-28 2018-10-04 Natco Pharma Limited Improved process for the preparation of pirfenidone
CA3108048A1 (en) 2017-07-31 2019-02-07 Washington University Pirfenidone derivatives for modulation of b lymphocyte activity and organ protection
ES2886152T3 (es) 2017-12-11 2021-12-16 Laurus Labs Ltd Un procedimiento mejorado para la preparación de pirfenidona
CN112409246B (zh) * 2019-08-21 2023-04-07 北京凯因科技股份有限公司 一种吡非尼酮的晶型及其制备方法
CN115666533A (zh) * 2020-04-22 2023-01-31 永进药品工业株式会社 具有改善的安全性和稳定性的含吡非尼酮的肠溶包衣制剂及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3839346A (en) * 1972-12-18 1974-10-01 Affiliated Med Res N-substituted pyridone and general method for preparing pyridones
CA2099868C (en) * 1991-01-31 2002-04-02 Thomas Richard Belliotti Substituted 4,6-di-tertiary-butyl-5-hydroxy-pyrimidines
WO2002085858A1 (fr) * 2001-04-20 2002-10-31 Asahi Glass Company, Limited Procede de production d'un derive de piperidine purifie
KR100898888B1 (ko) * 2001-08-06 2009-05-21 시오노기세이야쿠가부시키가이샤 5-메틸-1-페닐-2(1ｈ)피리디논의 제조 방법
CN1218942C (zh) 2002-06-11 2005-09-14 中南大学湘雅医学院 抗纤维化吡啶酮化合物及其生产工艺方法
CN100396669C (zh) * 2006-03-15 2008-06-25 浙江省医学科学院 一种抗纤维化药物吡非尼酮的制备方法
MX2007006349A (es) 2007-05-29 2009-02-18 Cell Therapy And Technology S Nuevo proceso de sintesis para la obtencion de 5-metil-1-fenil-2-(ih)-piridona, composicion y uso de la misma.
KR101583737B1 (ko) 2007-06-20 2016-01-11 오스펙스 파마슈티칼스, 인코포레이티드 섬유증 저해제로서의 치환된 ｎ-아릴 피리디논
US20090131485A1 (en) * 2007-09-10 2009-05-21 Concert Pharmaceuticals, Inc. Deuterated pirfenidone

Also Published As

Publication number Publication date
MA33489B1 (fr) 2012-08-01
WO2010141600A2 (en) 2010-12-09
ES2538103T3 (es) 2015-06-17
NI201100211A (es) 2012-08-01
DK2440543T3 (en) 2015-05-18
NZ596872A (en) 2013-12-20
JP2016026196A (ja) 2016-02-12
IL216565A0 (en) 2012-03-01
BRPI1011015A2 (pt) 2018-02-14
CL2011003069A1 (es) 2012-05-25
BRPI1011015B1 (pt) 2020-11-10
EP2440543A4 (en) 2012-11-21
PT2440543E (pt) 2015-07-03
SG176648A1 (en) 2012-01-30
AU2010256693A1 (en) 2012-01-12
US20150368200A1 (en) 2015-12-24
EA021826B1 (ru) 2015-09-30
AP3630A (en) 2016-03-08
RS54031B1 (en) 2015-10-30
KR101734858B1 (ko) 2017-05-12
HN2011003187A (es) 2015-02-02
CA2764043A1 (en) 2010-12-09
US20130345430A1 (en) 2013-12-26
JP2012528877A (ja) 2012-11-15
EA201101695A1 (ru) 2012-05-30
HUE026014T2 (en) 2016-05-30
PE20120398A1 (es) 2012-05-13
CA2764043C (en) 2018-01-16
AU2010256693B2 (en) 2015-09-17
ZA201108794B (en) 2013-03-27
KR20120016277A (ko) 2012-02-23
US20150065720A1 (en) 2015-03-05
JP5848244B2 (ja) 2016-01-27
US8519140B2 (en) 2013-08-27
IL216565A (en) 2015-06-30
US20110003863A1 (en) 2011-01-06
TWI434833B (zh) 2014-04-21
GEP20156223B (en) 2015-01-26
TN2011000615A1 (en) 2013-05-24
PL2440543T3 (pl) 2015-09-30
US20140221660A1 (en) 2014-08-07
AR076974A1 (es) 2011-07-20
EP2440543A2 (en) 2012-04-18
WO2010141600A3 (en) 2011-04-21
HRP20150696T1 (hr) 2015-08-28
US20120016133A1 (en) 2012-01-19
EP2440543B1 (en) 2015-04-15
TW201043602A (en) 2010-12-16
SI2440543T1 (sl) 2015-06-30
MY162443A (en) 2017-06-15
UA106759C2 (uk) 2014-10-10
CN102482255A (zh) 2012-05-30
AP2012006052A0 (en) 2012-02-29
MX2011012654A (es) 2012-01-12

Similar Documents

Publication Publication Date Title
BRPI1011015B8 (pt) método para sintetizar pirfenidona
WO2017100726A8 (en) Methods for treating huntington's disease
NZ734714A (en) Methods of purifying cannabinoids, compositions and kits thereof
BR112015005891A2 (pt) método de sintetizar análogos do hormônio da tireoide e polimorfos destes
EA200600323A1 (ru) γd-КРИСТАЛЛИЧЕСКАЯ ФОРМА ГИДРОХЛОРИДА ИВАБРАДИНА, СПОСОБ ЕЁ ПОЛУЧЕНИЯ И ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, КОТОРЫЕ ЕЁ СОДЕРЖАТ
MX2010001605A (es) Metodo para producir olefinas fluoradas.
BRPI0518647A2 (pt) processo para a produÇço de um composto, e, composto
NO20090755L (no) Amino-imidazoloner og deres anvendelse som et medikament for behandling av kognitiv svekkelse, Alzheimers sykdom, neurodegenerering og demens
SG10201804026WA (en) Inhibitors of influenza viruses replication
NO20092692L (no) MAPK/ERK kinaseinhibitorer
DK1751093T3 (da) Substituerede cyklohexyleddikesyre-derivater
TN2010000219A1 (en) 5-[(3,3,3-trifluoro-2-hydroxy-1-arylpropyl)amino]-1h-quinolin-2-ones, a process for their production and their use as anti-inflammatory agents
SG11201906688VA (en) Novel ester compounds, method for the production thereof and use thereof
TW200716564A (en) Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents
WO2013152277A3 (en) Moenomycin analogs, methods of synthesis, and uses thereof
NO20084301L (no) Tetrahydronaftalenderivater, fremgangsmate for deres fremstilling og anvendelse derav som anti-inflammatoriske midler
ES2333026T3 (es) Derivados de ciclohexil-1,4-diamina sustituidos.
WO2016183120A8 (en) Inhibitors of influenza viruses replication
EA201690467A1 (ru) Промышленный способ синтеза улипристала ацетата и его 4'-ацетильного аналога
UA113988C2 (xx) Спосіб стабілізації бета-напівгідрату штукатурного гіпсу
CY1110944T1 (el) Νεα παραγωγα κυκλοαλκυλιωμενων βενζοθειαδιαζινων, μεθοδος παρασκευης αυτων και οι φαρμακευτικες συνθεσεις που τα περιεχουν
ATE512134T1 (de) Verfahren zur herstellung von 5-benzyloxy-2-(4- benzyloxyphenyl)-3-methyl-1h-indol
WO2008096373A3 (en) Process for synthesizing highly pure nateglinide polymorphs
BRPI0514000A (pt) método para a produção de derivados de diarilcicloalquila
CY1116508T1 (el) Βελτιωμενη μεθοδος για τη συνθεση πιρφενιδονης

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25G Requested change of headquarter approved

Owner name: INTERMUNE, INC. (US)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 10/11/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 02/06/2010 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF